Board

The main responsibility of the board of directors

The main responsibility of the board of directors is to, on behalf of the shareholders, manage the company’s business and operations and be responsible for the company’s organisation. The chairman of the board leads the work of the board. Immediately following the AGM the board shall have founding meeting and during the year the board shall meet regularly but in addition whenever requested. At the founding meeting resolutions are taken on signing on behalf on company, adoption of written instructions for the CEO and for the financial reporting and the rules of procedure for the board. The meetings of the board of directors includes i.e., the company’s financial situation, the development of the operations and other current topics where the board shall have information. The board of directors have the supervision of the work of the CEO, i.e. follow up that the CEO executes the decisions taken by the board of directors. Further, the board of directors prepares and proposes principles for remuneration of the management of the company which principles are adopted by the AGM. The board of directors also prepares and proposes any incentive program before the AGM. The company’s auditor is present and reports at board meetings whenever necessary. The board of directors is qualified to take any resolution if more than half of the directors are present at the meeting. Currently Isofol’s board of directors consists of five directors.

Chairman of the board

Ulf has been a director of Isofol since 2010 and has been its clinical and regulatory expert. He has a long and successful experience within oncology research and development including leading positions in the United States in Celgene, Takeda, Pfizer and Eli Lily. Ulf has had key roles in the clinical development and market approval of drugs such as Alimta® (pemetrexed), Revlimid® (lenalidomide), Vidaza® (azacitidine) and Abraxane (nab + paclitaxel). In addition, Ulf has participated in several major Due Diligence processes that have resulted in multi-billion acquisitions, including Celgene’s acquisitions of Abraxis and Pharmion.

Position: Chairman of the board

Elected: 2018

Year of birth: 1951

Holdings*: 100 000

Independent in relation to the company and its management: No

Independent in relation to larger shareholders: Yes

*Own or related natural or legal person holding shares and other financial instruments in the company. Holdings as of October 4, 2018.

MD, Ph.D, Prof. / Director

Bengt is the founder of Isofol Medical and the head of surgical oncology at Sahlgrenska University Hospital, Gothenburg, Sweden. He co-discovered the positive effects of Leucovorin on 5-FU that created the widely used combination treatment against colorectal cancer called 5-FU-LV.

Bengt is also the founder of Carmel Pharma. Since 1996, he is a member of the scientific committee of the Swedish Cancer Society and he has been a member of its scientific committee for two terms. He is a member of the American Society of Clinical Oncology, European Surgical Society, Swedish Surgical Society and the Swedish Society of Colon and Rectal Surgeons.

Position: Director / Board Member

Elected: 2008

Year of birth: 1947

Holdings*:3 454 811 shares

Independent in relation to the company and its management: No

Independent in relation to larger shareholders: No

*Own or related natural or legal person holding shares and other financial instruments in the company. Holdings as of 1th of March.

Anders led Astra’s research, development and strategic marketing activities within cardiology and gastrointestinal areas up to 1998, when he was appointed professor in industrial economy at Chalmers. After 2002 Anders has been active within Life Science as inventor or advisor to different companies and authorities. He has had responsibility for development and market introduction of at least eight new pharma drugs, of which some have been among the most sold in the world.

Position: Director / Board Member

Elected: 2018

Year of birth: 1942

Holdings*: 0

Independent in relation to the company and its management: Yes

Independent in relation to larger shareholders: Yes

*Own or related natural or legal person holding shares and other financial instruments in the company. Holdings as of October 4, 2018.

PhD, MBA

Magnus he has been active in the field of business development at AstraZeneca since 2006. He has also been responsible for the Business Development group at Astra’s site in Gothenburg and participated in a large number of licensing and other types of transactions with both big pharma and small biotech. Since 2014, Magnus is leading AZ BioVentureHub AB, a commitment to strengthen the national development of start-up Life Science companies.

Position: Director / Board Member

Elected: 2018

Year of birth: 1964

Holdings*: 0

Independent in relation to the company and its management: Yes

Independent in relation to larger shareholders: Yes

*Own or related natural or legal person holding shares and other financial instruments in the company. Holdings as of October 4, 2018.

Paula´s skillset spans global commercialization planning, pre-launch preparation, major launch initiatives for first-in-class agents, and patient advocacy. She has been involved in introducing and supporting brands like Imbruvica (ibrutinib), Glivec/Gleevec (imatinib), Aranesp (darbopoetin), Camptosar (irinotecan), and Vectibix (panitumumab). In addition, Paula has held top-tier positions, as well as consulted, for major companies including Pharmacia (Pfizer), Novartis, Amgen, Proteolix (Onyx), Dendreon, Incyte, and Pharmacyclics, among others. Paula is presently the Chief Commercial Officer at Oncopeptides AB.

Position: Director / Board Member

Elected: 2018

Year of birth: 1958

Holdings*: 0

Independent in relation to the company and its management: Yes

Independent in relation to larger shareholders: Yes

*Own or related natural or legal person holding shares and other financial instruments in the company. Holdings as of October 4, 2018.

Ph.D, MBA/Director

Jonas is the CEO and owner of Deallus Consulting, a life science competitive strategy consultancy based out of London with offices in New York, Princeton, Los Angeles and Tokyo. The company works with 20 of the 25 top biopharmaceutical companies advising on commercial and competitive strategy. Jonas has an Executive MBA from Stockholm School of Economics, a Ph.D. in Neurophysiology and a B.Sc. in Psychology.

Jonas has worked in the USA as the Head and Director of Competitive Intelligence at Amgen Inc. Previously, Jonas worked for Therapy Area Pain Control within AstraZeneca R&D. Prior to joining the life science sector, Jonas was an Assistant Professor and acting Deputy Director at the Department of Musculoskeletal Research, National Institute for Working Life in Sweden.

He has provided advice to many of the world’s leading biopharmaceutical organizations across a range of sectors and is a recognized speaker at Business schools and numerous conventions and forums.

Position: Director / Board Member

Elected: 2011

Year of birth: 1969

Holdings*: 100 000 shares

Independent in relation to the company and its management: Yes

Independent in relation to larger shareholders: Yes

*Own or related natural or legal person holding shares and other financial instruments in the company. Holdings as of 1th of March.

MD, PhD / Director

Dr. Alain Herrera, MD, PhD is an oncologist / hematologist that has contributed directly to the worldwide registration of, among others, the cytostatic oxaliplatin. Oxaliplatin in combination with fluorouracil and leucovorin constitute one of today’s basic regimens, FOLFOX, in treatment of colorectal cancer. Currently Dr. Herrera operates as a Senior Consultant within the field of Oncology. Prior to this Dr. Herrera held the position of Vice President of Global Oncology Business Strategy and Development at Sanofi and before that he was Head of Global Oncology Franchise at Sanofi. Dr. Herrera has also served as Chairman of Chiron Therapeutics Europe and as Managing Director of Pierre Fabre Oncology Laboratories. Dr. Herrera is part of the Supervisory Board of, among others; IDDI, Nanobiotix, PDCline Pharma, Gustave Roussy-Transfert and Arcad Foundation.

Position: Director

Elected: May of 2018

Year of birth: 1950

Holdings*: 0

Independent in relation to the company and its management: Yes

Independent in relation to larger shareholders: Yes

*Own or related natural or legal person holding shares and other financial instruments in the company. Holdings as of 1th of March.

About Isofol

Isofol Medical AB (publ) is a biotech company within the field of oncology developing arfolitixorin, primarily as a treatment for advanced colorectal cancer and as a rescue drug after high-dose methotrexate treatment in osteosarcoma (bone cancer).